早期恶性卵巢生殖细胞肿瘤淋巴结清扫对生存的影响
基于美国国家癌症数据库2018-2022年740例T1期恶性卵巢生殖细胞肿瘤患者，47.3%接受淋巴结清扫且使用率从53.3%降至36.2%。倾向评分加权后，淋巴结清扫与生存改善无关（aHR 1.23，95%CI 0.38-4.06），但与辅助化疗率更高相关。
要点
- T1期恶性卵巢生殖细胞肿瘤中淋巴结清扫率逐年下降，2018年53.3%降至2022年36.2%。
- 淋巴结转移率仅6.6%，中位检出淋巴结数9枚，以无性细胞瘤最常见。
- 倾向评分加权后淋巴结清扫未改善生存（aHR 1.23，95%CI 0.38-4.06）。
核心结论
- T1期恶性卵巢生殖细胞肿瘤中，淋巴结清扫与生存改善无关，但与辅助化疗使用率更高相关。
- 鉴于淋巴结转移率低且生存结局良好，选择性淋巴结清扫可能是合适的。
研究设计与样本
- 回顾性队列研究，使用美国国家癌症数据库，纳入2018-2022年诊断的740例T1期恶性卵巢生殖细胞肿瘤女性。
- 采用多变量对数线性回归分析与淋巴结清扫相关的因素，并应用倾向评分逆概率处理加权（IPTW）评估淋巴结清扫与生存的关联。
主要发现
- 740例患者中47.3%接受淋巴结清扫，使用率从2018年53.3%下降至2022年36.2%（P=0.02）。
- 无性细胞瘤组织学（aRR 1.78，95%CI 1.19-2.66）、肿瘤大小>150 mm（aRR 1.44，95%CI 1.03-2.01）及行子宫切除术（aRR 1.40，95%CI 1.04-1.87）与淋巴结清扫可能性增加相关。
- 中位检出淋巴结数为9枚（IQR 4-16），6.6%的病例发现淋巴结转移，最常见于无性细胞瘤。
- 倾向评分IPTW后，淋巴结清扫组接受辅助化疗的比例更高（52.8% vs 44.7%；SMD=0.16）。
- 淋巴结清扫与生存改善无关（aHR 1.23，95%CI 0.38-4.06）。
关键数值与推荐
- 淋巴结清扫使用率从2018年53.3%降至2022年36.2%（P=0.02）。
- 淋巴结转移率为6.6%，中位检出淋巴结数9枚（IQR 4-16）。
- 淋巴结清扫与生存的aHR为1.23（95%CI 0.38-4.06）。
- 辅助化疗率淋巴结清扫组52.8% vs 非清扫组44.7%（SMD=0.16）。
临床怎么用
- 对于T1期恶性卵巢生殖细胞肿瘤，可考虑选择性而非常规行淋巴结清扫。
- 淋巴结清扫可能增加辅助化疗使用，决策时需权衡利弊。
局限性
- 回顾性数据库研究，可能存在选择偏倚和未测量混杂因素。
- 淋巴结清扫与辅助化疗的关联可能受适应症混杂影响。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
OBJECTIVE: Malignant ovarian germ cell tumors (MOGCTs) are rare non-epithelial ovarian malignancies. Although comprehensive surgical staging, including lymphadenectomy, is recommended by current guidelines, the prognostic benefit in early-stage disease remains uncertain. We evaluated patterns of lymphadenectomy use and its association with survival in stage T1 MOGCTs. METHODS: Using the National Cancer Database, we identified women with stage T1 MOGCTs diagnosed between 2018 and 2022. Multivariable log-linear regression was used to identify factors associated with lymphadenectomy. Propensity score inverse probability of treatment weighting (IPTW) was applied to estimate the association between lymphadenectomy and survival using weighted Kaplan-Meier and Cox proportional-hazards models. RESULTS: Among 740 patients, 47.3% underwent lymphadenectomy, with use declining from 53.3% in 2018 to 36.2% in 2022 (P = 0.02). Dysgerminoma histology (aRR 1.78, 95% CI: 1.19-2.66), larger tumor size (>150 mm, aRR 1.44, 95% CI: 1.03-2.01), and performance of hysterectomy (aRR 1.40, 95% CI: 1.04-1.87) were associated with increased likelihood of undergoing lymphadenectomy. The median number of nodes examined was 9 (IQR 4-16), with nodal metastases identified in 6.6% of cases, most commonly among dysgerminomas. After PS IPTW, patients who underwent lymphadenectomy were more likely to receive adjuvant chemotherapy (52.8% vs. 44.7%; SMD = 0.16), and lymphadenectomy was not associated with improved survival (aHR 1.23, 95% CI: 0.38-4.06). CONCLUSIONS: In stage T1 MOGCTs, lymphadenectomy was not associated with improved survival but was associated with higher rates of adjuvant chemotherapy use. Given the low rate of nodal metastasis and excellent survival outcomes, a selective approach to lymphadenectomy may be appropriate.
引用
- Ludmir D, Huang Y, Xu X, et al. Impact of lymphadenectomy on survival outcomes for stage I malignant ovarian germ cell tumors. Gynecol Oncol. 2026. PMID: 42090882. doi:10.1016/j.ygyno.2026.04.016
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。